Biofrontera AG, a specialist for the treatment of sun-induced skin cancer, announced the market launch of Ameluz and BF-RhodoLED in Israel by Biofrontera’s partner Perrigo.
Prof. Dr. Hermann Lübbert, CEO of Biofrontera, commented, “We are pleased to be working with Perrigo and believe they will be effective in launching the treatment in Israel, allowing more patients to benefit from our technology. We look forward to expanding our global footprint and this commercial launch in Israel represents another major milestone for our company, as our treatment is now available in 14 countries.”
Ameluz, a topical prescription drug, is used in combination with the medical device BF-RhodoLED for photodynamic therapy treatment (PDT). The combination treatment is labeled for lesion- and field-directed treatment of actinic keratosis (AK) in the U.S., and additionally for the treatment of field cancerization and superficial and nodular basal cell carcinoma in the EU.
Perrigo is a global pharmaceutical company that is active for both medicinal products and devices, and garners a leading position in the field of dermatology in Israel. Biofrontera entered into a licensing agreement with Perrigo Israel in January 2014 for the marketing of Ameluz and BF-RhodoLED in Israel. In November 2014, Perrigo Israel filed the marketing approval dossier with the Ministry of Health in Israel (IMOH) and Ameluz received approval in May 2016. Subsequently, BF-RhodoLED lamp was registered in Israel in May 2017.
In Israel, Ameluz and BF-RhodoLED currently are approved for the treatment of AK. Discussions on label expansions on field cancerization and basal cell carcinoma are in progress with the Ministry of Health.
Biofrontera AG is a biopharmaceutical company specializing in the development, sale, and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 100 employees worldwide, develops and distributes products for the care, protection, and treatment of the skin.
(Source: Biofrontera AG)
